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Definition 
NNK [ 4- (methylnitrosamino )-1- (3-pyridyle)-1-
butanone], a nicotine-derived nitrosaminoketone, 
is contained in tobacco smoke and is known to 
be a lung carcinogen. It is one of the most po­
tent carcinogenic nitrosamines in laboratory 
animals .and has, therefore, been implicated as 
a major cause of tobacco associated lung can­
cer111. 
There are about 55 carcinogens in cigarette 
smoke that have been evaluated by the 
International Agency for Research on Cancer 
(IARC) and for which there is sufficient evi­
dence for carcinogenicity in either laboratory 
animals or humans121. NNK is a potent lung car­
cinogen in rats, mice, and hamsterd31, being the 
only compound in cigarette smoke that has so 
far been found to induce lung tumors 
systemically in all three commonly used rodent 
models. The organospecificity of NNK for the 
lung is remarkable; it induces tumors of the 
lung, mainly adenomas and adenocarcinomas, 
independent of the route of administration and 
in both susceptible and resistant strains of 
mice (Table 1)131. It has been proposed as par­
tially responsible for the recent dramatic m­
crease in adenocarcinoma of the lung141. 
Structure 
Nicotine is a tertiary amme consisting of a 
pyridine and a pyrrolidine ring and NNN is 
formed by nitrosation of the latter. Production 
of NNK involves nitrosation under opening of 
the pyrrolidine ring (fig .2). 
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Fig.2 structure of NNK 
Exposure 
NNK 4- (me thy lni trosamino) -1- ( 3-pyridy le) -1-
bu tanone has been found in a variety of to­
bacco products (chewing tobacco, snuff, 
cigarettes and cigars), in mainstream and side 
stream smoke from cigars and cigarettes, and 
in the saliva of chewers of betel quid with to­
bacco and oral snuff users. Daily exposure to 
tobacco specific nitrosamines is estimated as up 
to 20µ g in smokers and 68µ g in snuff dippers 
(5) 
Experi mental data 
NNK was tested for carcinogenicity in several 
studies by subcutaneous injection in rats and 
hamsters and by intraperitoneal injection in 
mice. In hamsters, it induced benign and malig­
nant tumors of the nasal cavity, trachea and 
lung, even after a single administration. In 
mice, NNK and its metabolites 4-
(methylnitrosamino)-1- (3 - pyridyl - N- oxide)-1-
butanone and 4- (methylnitrosamino)-1- (3-
pyridyl)butan-lol, induced benign and 
malignant tumors of the lung. Both sensitive 
and resistant mouse strains develop lung tu­
mors when treated with NNK, although the 
incidence and multiplicity in resistant strains 
are lower and the tumors require a longer time 
to develop (Table. 1) 131• The lung is the main 
target of NNK carcinogenicity although liver 
and forestomach tumors are seen occasionally. 
The A/ J mouse, a sensitive strain, has been 
used extensively for studies of lung induction 
by NNK. The most commonly applied model 
features a single ip dose of 10 µ mol 161• NNK 
and its metabolites can cross the placental bar­
rier in mice and can be metabolically activated 
by mouse fetal tissues. 
Table 1 . Induction of lung tumors by NHK 
( 4-( methy lnitrosamino )-1-( 3-pyridy 1)-1-butanone) 
Species and strain Route 
Mouse 
A/J i.p. gavage 
Sen car Skin 
BALB/c Oral 
Swiss Oral, 1.p. 
C3b6Fl 1.p. 
C3H/HeJ i.p. 
C57/BL/6 1.p. 
(Al JxTSG-p53 )F2 1.p. 
F344 rat s.c., p.o., oral swab, 
gavage, intravesicular 
Syrian golden hamster s.c., application to cheek pouch 
Mink s.c. 
i.p. - intraperitoneal; p.o. - per os (i.e., orally via 
drinking water); and s.c.- subcutaneous. 
Mechanisms of NNK induction of lung cancer 
There are general principles for understanding 
the mechanism of tobacco carcinogenesis. 
The following fig. (1) illustrates the overall 
framework for discussing these principles. 
1 . Carcinogens form the link between nicotine 
addiction and lung cancer. 
2 . Nicotine addiction is the reason that people 
continue to smoke 111• 
3 . While nicotine itself is not considered to be 
carcinogenic, each cigarette contains a mix­
ture of carcinogens, including small doses 
of polycyclic aromatic hydrocarbons 
(PAHs) and 4- (methylnitrosamino)-1- (3-
-77-
pyridy0-1- butanone (NNK) among other 
lung carcinogens, tumor promoters and 
cocarcinogens 121• 
4. Carcinogens such as NNK& PAHs require 
metabolic activation to exert their effects; 
there are competing detoxification path­
ways, and the balance between metabolic 
activation and detoxification differs among 
individuals and will affect cancer risk. 
5 . The metabolic activation process leads to 
the formation of DNA adducts, which are 
carcinogen metabolites bound covalently to 
DNA, usually at adenine or guanine. 
6. If DNA adducts escape cellular repair 
mechanisms and persist, they may lead to 
miscoding, resulting in a permanent muta­
tion. 
7. Cells with damaged DNA may be removed 
by apoptosis, or programmed cell death. 
8. If a permanent mutation occurs in a critical 
region of an oncogene or tumor suppressor 
gene, it can lead to a- activation of the 
oncogene or b- deactivation of the tumor 
suppressor gene. 
9 . Multiple events of this type lead to aber­
rant cells with loss of normal growth con­
trol and ultimately, to lung cancer. 
There is now a large amount of data on 
mutations in human KRAS and p53 (also 
known as TP53) genes in lung tumors from 
smokers, and attempts have been made to 
link these mutations to specific carcinogens 
in tobacco smoke . 
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Fig.1 scheme linking nicotine addiction 
and lung cancer via tobacco smoke 
carcinogens and their induction of 
multiple mutations in critical genes. PAH; 
polycyclic aromatic hydrocarbons; NNK ; 
4·(methylnitrosamino)-1-(pyridyl)· 1 • 
butanone. 
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NNK :uptake, metabolism, and adduct forma­
tion 
Fewer than 20% of smokers will get cancer18). 
Susceptibility will depend in part on the balance 
between carcinogen metabolic activation and 
detoxification in smokers. 
Carcinogens are enzymatically transformed to 
a series of metabolites as the exposed organ­
ism attempts to convert them to forms that are 
more readily excreted. 
NNK metabolism pathways are illustrated in 
(fig. 3). 
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Fig.3 metabolic pathway of NNK P450-
cytochrome P450;NNAL- 4-
(methylnitrosamino)-1-(3-pyridyl)-1-
butanoL 
DNA adducts 
1 . Metabolism of NNK and NNAL 
Five types of transformations has been ob­
served: Carboxyl reduction, Pyridine oxidation, 
a - Methylene hydroxylation, a - Methyl hy­
droxylation ADP adduct formation and 
Denitrosation. 
a . Carboxyl reduction; reduction of the NNK 
carboxyl group produces NNAV9), the 
predominant NNK metabolite formed in 
vitro with many tissues. This is the case 
in rodent and human liver, as will as in 
human lung and in rat intestine. NNAL 
has carcinogenic activity similar to NNK 
and indeed can be oxidized to form NNK. 
NNAL can form NNAL-Gluc which is 
probably a detoxification product. P450 
plays little role in NNAL formation. 
b. Pyridine oxidation; pyridine oxidation re­
sults in the formation of NNAL N-oxide, 
the major metabolite of NNK in rat and 
mouse lung m1crosomes. Pulmonary 
P450s are the major catalysts of pyridine 
- 78 -
n-oxidation as well as a -hydroxylation 
of NNK and NNAL°0). 
c. a - Methylene hydroxylation ; hydroxyla­
tion of the methylene carbon adjacent to 
the N-nitroso group produces the unsta­
ble intermediate a -methylenehydroxy-NN 
K, which spontaneously decomposes to 
methane diazohydroxide. This methylates 
DNA forming a variety of adducts. 
d. a - Methyl hydroxylation; hydroxylation 
of the NNK methyl group yields a -hyd 
roxymethyl NNK which decomposes spon­
taneously to formaldehyde and 
diazohydroxide or diazonium ions. The 
latler pyriloxobutylate DNA and are im­
portant in NNK carcinogenesis. 
2. Enzyme involvement in NNK metabolism 
The initial steps are usually carried out by 
cytochrome P450 (P450s) 
enzymes, encoded by the CYP family of genes, 
which oxygenate substrates au. Other enzymes 
such as lipoxygenases, cyclooxygenases, 
myeloperoxidase, and monoamme oxidases, 
may also be involved, but less frequently. P450s 
1A2, 2A, 2Bl, and 3A play roles in oxidative 
metabolism of NNK in rats and mice. 
a. Carboxyl reduction; this reaction is medi­
ated by carbonyl reductases. 11- f3 -Hydro 
xysteriod dehydrogenase, a microsomal 
enzyme responsible for the 
interconversion of active 11-
hydroxyglucocorticoids to inactive 11-oxo 
forms has been identified as one 
carbox??yl reductase involved in the re­
duction of NNK to NNAL. 
b. Pyridine oxidation; there is strong evi­
dence that P450 2Bl is one of the major 
rat hepatic P450 forms responsible for 
conversion of NNK to NNK N-oxide. 
c. a - Methylene hydroxylation; subtypes of 
P450s such as P450 1Al,2Al,2 Bl,2F,2A4, 
2A6 and 3A4, have been found to have a 
role in this reaction. 
d. a - Methyl hydroxylation; this is proba­
bly a P450 ?mediated reaction. 
3. DNA binding of NNK and NNAL 
Some of the metabolites produced by the P450s 
react with DNA or other 
macromolecules to form covalent binding prod­
ucts known as adducts. Their generation is re­
ferred to as metabolic activation, other 
reactions being considered as detoxification 
pathways. (Fig 3). 
1 . The major metabolic activation pathway of 
NNK and its mam metabolite, 4-
(methylnitrosamino )-1- ( 3-pyridy0-1-butanol 
(NNAL), occur by hydroxylation of the 
carbons adjacent to the N- nitroso group 
( a -hydroxylation), which leads to the for­
mation of two types of adducts: methyl ad­
ducts, such as 7.methylguanine or 06 -
methylguanine, and pyridyloxobutyl 
adducts. 
2 . 06 -methylguanine plays a critical role in 
mouse lung tumorigenesis by NNK <'1• 
Thus there are two major types of NNK­
DNA adducts: methyl adducts formed by 
a - Methylene hydroxylation and 
pyridyloxobutyl adducts formed by a -
Methyl hydroxylation. 
DNA methylation ( a - Methylene hydroxy­
lation). a - Methylene hydroxylation of 
NNK yields methane diazohydroxide 
and/ or the methyldiazonium ion, which re­
acts with DNA producing7-mG,06-mG, and 
04·mT. DNA methylation by NNK has been 
observed in a number of in vitro studies 
with different systems capable of metabolic 
activation, including rat lung cells and lung, 
liver, or nasal mucosal microsomes, rat 
oral tissue, and hamster lung. 
DNA Pyridyloxobutylation ( a - Methyl hy­
droxylation). Pyridyloxobutyl adducts m­
hibit AGT, the enzyme responsible for 
repair of 06-mG. 
DNA repair processes 
DNA repair processes are important m deter­
mining whether DNA adducts persist. Because 
smoking is a chronic habit, we can expect a 
steady-state DNA adduct level to be achieved 
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by the opposing effects of damage and repair: 
direct repair, base excision repair and nucleo­
tide excision repair. With respect to smoking 
and lung cancer, direct repair of 06 -
methyldeoxyguanosine by 06 -methylguanine­
DNA alkyltransferase (AGT) and nucleotide 
excision repair of PAH-DNA adducts would ap­
pear to be the most relevant processes. In 
smokers, the AGT that would repair 06 -
methylguanine formed from NNK, might be in­
hibited by pyridylobutylated DNA, as shown in 
mice (IJ!. 
Effects of NNK on tumor suppressor genes and 
oncogenes. 
As indicated in fig <11, the direct interaction of 
metabolically activated carcinogens with critical 
genes such as the p53 tumor suppressor gene 
and the Kirsten-ras (Kras) oncogene, is central 
to the hypothesis that specific carcinogens form 
the link between nicotine addiction and lung 
cancer. 
The p53 gene 
The p53 gene plays a central role in the delicate 
balance of cellular proliferation and death. It is 
mutated in about half of all cancer types, in­
cluding more than 50% of lung cancers. Point 
mutations at G are common. In a sample of 550 
p53 mutations in lung tumors, 33% were G-T 
transversions while 26% were G-A transitions. 
(A Purine -Pyrimidine or Pyrimidine- Purine 
mutation is ref erred to as a trans version, while 
a purine -purine or pyrimidine- pyrimidine 
mutation is called a transition). 
A positive relationship between lifetime ciga­
rette consumption and the frequency of p53 
mutations and of G-T transversions on the 
non-transcribed DNA strand also has been 
noted . These observations are generally consis­
tent with the fact that most activated carcino­
gens react predominantly at G and the repair 
of the resulting adducts would be slower on the 
nontranscribed strand, and thus support the 
hypothesis outlined in fig.I cu. 
Many factors influence the type of mutations 
Hekmat Osman Abdel Aziz, Kazuhiro Nomoto, Yasuo Ykan 
of p53. These include the type of DNA adduct 
formed, the extent to which it is repaired, its 
sequence context, and the DNA polymerases in­
volved. 
It has been demonstrated that cytosine 
methylation greatly enhances guanine 
alkylation at all CpG sites in the p53 gene by a 
variety of carcinogens. 06-Alkylguanine, formed 
from nitrosamines, is another likely cause of 
G-->- A transitions . NNK derived intermediates 
can cause G-->-T transversion. 
Kras gene; 
Mutations in codon 12 of Kras are found in 
24%-50% of human primary adenocarcinomas 
but are rarely seen in other lung tumor types(!�. 
These mutations are more common in smokers 
and exsmokers than in non smokers, which 
suggests that they may be induced by direct re­
action with the gene of an activated tobacco 
smoke carcinogen . 
In the mouse, the 06- methylguanine pathway 
of NNK metabolic activation is dominant, re­
sulting in a high percentage of GGT- GAT 
mutations in codon 12 of the Kras gene. 
The pl6;0•4• tumor suppressor gene is inactivated 
in more than 70% of human non-small-cell lung 
cancers, via homozygous deletion or in associa­
tion with aberrant hypermethylation of the pro­
moter region. 
In the rat, 94% of the adenocarcinomas induced 
by NNK have been found to be 
hypermethylated at the pl6 gene promoter. This 
change is frequently detected in hyperplastic le­
sions and adenomas, which are precursors to 
the adenocarcinomas induced by NNK. Similar 
results were obtained for human squamous cell 
. carcinomas of the lung. Methylation of pl6 is 
associated with loss of expression in tumorsand 
precursor lesions, indicating functional inactiva­
tion of both alleles. Aberrant methylation of 
pl6 has been suggested as an early marker of 
lung cancer(!". 
Reti noblastorna (RB) 
The expression of cell cycle proteins 1s related 
-
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to pl6 and retinoblastoma (RB) genes; NNK­
induced mouse lung tumors appear to resemble 
human non-small-cell lung cancers in cell cycle 
proteins M. 
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